# US 2026/0097131 A1 · Compositions and methods for reprogramming diseased musculoskeletal cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0097131 A1
- Document ID: US20260097131A1
- Status: Published application
- Kind: A1
- Application number: 19/415,812
- Filed: 2025-12-11
- Published: 2026-04-09
- Earliest claimed: 2018-12-20
- Assignees: Ohio State Innovation Foundation; UMIP The University of Manchester Intellectual Property
- Applicants: Ohio State Innovation Foundation; UMIP The University of Manchester Intellectual Property
- Inventors: Devina WALTER; Shirley TANG; Judith HOYLAND; Safdar KHAN; Benjamin WALTER; Daniel GALLEGO-PEREZ; Natalia HIGUITA-CASTRO
- Web page: https://patentgrep.com/patent/US20260097131A1

## CPC

- A61K 48/0025: {wherein the non-active part clearly interacts with the delivered nucleic acid}
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- C07K 14/4702: {Regulators; Modulating activity}
- C12N 5/0652: {Cells of skeletal and connective tissues; Mesenchyme}
- C12N 15/85: for animal cells
- C12N 2800/107: for mammalian
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Disclosed herein are compositions and methods for reprogramming diseased musculoskeletal cells both in vitro and in vivo. In some embodiments, the disclosed method involves non-virally delivering intracellularly into the diseased musculoskeletal cells a polynucleotide comprising one or more nucleic acid sequences encoding one or more of the disclosed transcription factors.

## Claims

### Claim 1

A method for treating a musculoskeletal disease in a subject, comprising
(a) non-virally delivering intracellularly into musculoskeletal cells of the subject one or more transcription factor proteins selected from the group comprising HIF-1α, HIF-2α, T-box family protein, a Forkhead-box (FOX) family protein, a Mohawk family protein, Scleraxis, NFAT Family protein, C-1-1, PGC1α, Osterix, MEF2C, Sonic hedgehog pathway protein, PAX family protein, SOX family protein, notochord homeobox, Tenomodulin, Nkx3-2, RUNX2, API family proteins, Afp36, Ebf family proteins, MAF, NUPR1, Twist family protein, MAGED1, SATB2, LMP3, Oct family protein, Dlx family proteins, C/ECPs, ATF family proteins, SMADs, MEN family proteins, MSX family proteins, NF-1, SP3, Ob1, EGR family proteins, SIX family proteins, EYA family prteisn, PEA3, BCL6, Myo family Proteins, CSFR pathway proteins, SRG, GLI2, Sp4, ATF family proteins, ETV family proteins, and REST or polynucleotides encoding the one or more transcription factor proteins;
(b) exposing the musculoskeletal cells to an extracellular vesicle produced from a cell containing or expressing the one or more transcription factor proteins, or polynucleotides encoding the one or more transcription factor proteins.

### Claim 2 (depends on 1)

The method of claim 1, wherein the musculoskeletal cells comprises diseased nucleus pulposus (NP) cells, and wherein the one or more transcription factor proteins comprises HIF-1α, HIF-2α, a T-box family protein, a Sonic Hedgehod signalong pathway, PAX1, SOX family protein, NOTO, a Forkhead-box (FOX) family protein, or any combination thereof.

### Claim 3 (depends on 1)

The method of claim 1, wherein the musculoskeletal cells comprises annulus fibrosis (AF) cells, and wherein the one or more transcription factor proteins comprises a Mohawk family protein, Tenomodulin, PAX9, Scleraxis, or any combination thereof.

### Claim 4 (depends on 1)

The method of claim 1, wherein the musculoskeletal cells comprises cartilage endplate cells, and wherein the one or more transcription factor proteins comprises NFAT Family protein, C-1-1, PGC1α, Osterix, SOX family protein, Nkx3-2, MEF2C, or any combination thereof.

### Claim 5 (depends on 1)

The method of claim 1, wherein the musculoskeletal cells comprises Osteocytes, Osteoclasts, Osteoblasts, and wherein the one or more transcription factor proteins comprises RUNX2, Fox family proteins, API complex proteins, Afp36, Ebf famil proteins, Naf, Nef2c, Twist family proteins, MAGED1, SATB2, LMP3, OCT family proteins, KLF4, MYC, DLX family protens, C/EBPs, ATF family proteins, NFATc, SMADS, Menin, Msx family proteins, SP3, Ob-1, NF-1, or any combination thereof.

### Claim 6 (depends on 1)

The method of claim 1, wherein the musculoskeletal cells comprises Tenocytes and Ligament cells, and wherein the one or more transcription factor proteins comprises EGR family proteins, Scleraxis, NKx, SIX family proteins, EYA family proteins, PEA3 and Mohawk.

### Claim 7 (depends on 1)

The method of claim 1, wherein the musculoskeletal cells comprises Synoviocytes, and wherein the one or more transcription factor proteins comprises SOX family proteins, NFAT5, BCL-6, HIF-1α, and HIF-2α.

### Claim 8 (depends on 1)

The method of claim 1, wherein the musculoskeletal cells comprises Monocytes and Myofibriblasts, and wherein the one or more transcription factor proteins comprises Myo family proteins, PU1, CSFR Pathway proteins, EBPA, SRF, GLI2.

### Claim 9 (depends on 1)

The method of claim 1, wherein the musculoskeletal cells comprises Dorsal Root Ganglion Cells, and wherein the one or more transcription factor proteins comprises FOXO, SP4, ATF family proteins, ETV family proteins, SOX11, REST, RUNX1, and RUNX3.

### Claim 10

A non-viral vector comprising a polynucleotide comprising a nucleic acid sequence encoding two or more transcription factors selected from the group comprising Forkhead-box (FOX) family protein, a Mohawk family protein, Scleraxis, NFAT Family protein, C-1-1, PGC1α, Osterix, and MEF2C, and factors from Table 1 operably linked to an expression control sequence, wherein the non-viral vector is encapsulated in a liposome, microparticle, or nanoparticle suitable for intracellular delivery.
